Últimas noticias sobre ABVC BioPharma (NASDAQ:ABVC) Bolsa

ABVC BioPharma

ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.

ABVC BioPharma Inc

News

Laboratory Corporation Of America Holdings

NOWDiagnostics Partners With Labcorp To Expand Access To First FDA-Authorized OTC Syphilis Test In The U.S.; First To Know Syphilis Test To Be Available In Clinical And Hospital Settings By Late 2024, With Direct Patient Access Via Labcorp OnDemand In 2025

VS: 489% &#x7C; <a href="https://www.benzinga.com//node/41354474">Versus Systems shares are trading higher after the company announced a $2.5 million investment and licensing agreement with ASPIS.</a>
&nbsp;
NVAX: -32% &#x7C; <a href="https://www.benzinga.com//node/41355032">Novavax shares are trading lower after the FDA placed a clinical hold on the company's investigational new drug application for its COVID-19-influenza combination and standalone influenza vaccine candidates.</a>
&nbsp;
BDRX: 245% &#x7C; <a href="https://www.benzinga.com//node/41354484">Biodexa Pharmaceuticals shares are trading higher after the company announced it successfully appealed Nasdaq's delisting decision and was granted a time extension to demonstrate compliance with its listing rule.</a>

Movers

Trading Ideas

BDRX

NVAX

Market-Moving News for October 16th

Roth MKM analyst Scott Stember reinstates AutoZone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) with a Buy and announces $3634 price target.

Price Target

Initiation

Analyst Ratings

Roth MKM Reinstates Buy on AutoZone, Announces $3634 Price Target

Alaska Airlines Enhances Mileage Plan For 2025 With New Perks, Faster Elite Status Earning, And Expanded Options For Earning And Redeeming Miles; Single Loyalty Program Coming As Alaska And Hawaiian Airlines Merge

WIIM

ULTA

Ulta Beauty shares are trading lower after the company provided long-term business strategy plans and reaffirmed its F24 guidance.

A high-stakes power struggle has erupted between Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and activist investor Starboard Value, with Wall Street&#8217;s dealmaker, Alan Schwartz, and his firm, Guggenheim Partners, <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41199793/amid-pfizers-struggles-with-declining-demand-for-covid-19-treatments-activist-investor-starboard" rel="noreferrer noopener">caught in the crossfire</a>.
The activist investor had built a $1 billion&nbsp;stake&nbsp;in the U.S. drug maker. The tension peaked when Pfizer&#8217;s former CEO Ian Read and former CFO Frank D&#8217;Amelio, who initially supported Starboard&#8217;s campaign against Pfizer&#8217;s current CEO Albert Bourla, unexpectedly <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41264265/former-pfizer-executives-ian-read-and-frank-damelio-support-albert-bourlas-leadership-amid-starb" rel="noreferrer noopener">reversed their stance</a>.
Read and D&#8217;Amelio issued a statement expressing full support for Bourla and the board, though this sudden shift in allegiance left insiders puzzled.
Even more surprising was that the statement was released through Guggenheim, a firm that has enjoyed a close relationship with Pfizer and has earned approximately $172 million in advisory fees since 2011, most recently $48 million from the&nbsp;Seagen deal.
Speculation surrounds the reversal, with Jeff Smith, CEO of Starboard, claiming Pfizer pressured the ex-executives with potential legal consequences <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41274121/whats-going-on-with-pfizer-stock-on-thursday" rel="noreferrer noopener">and bonus clawbacks</a>.
Despite not playing an official role in the Starboard-Pfizer dispute, Guggenheim finds itself entangled in one of Wall Street&#8217;s most contentious activist campaigns.
The Financial Times <a target="_blank" href="https://www.ft.com/content/1546d1e6-3bd6-43d8-b17a-919308096ef0" rel="noreferrer noopener">notes</a> that Pfizer has since turned to rival boutique firm PJT Partners to lead its defense, distancing itself from its long-time advisor in this high-profile clash.
Starboard&#8217;s frustration stems from Pfizer&#8217;s declining performance since its COVID-19 vaccine windfall. The company has faced criticism for a series of costly acquisitions, including its $43 billion <a target="_blank" href="https://www.benzinga.com/general/biotech/23/12/36198526/pfizer-clears-required-regulatory-hurdles-to-complete-43b-seagen-acquisition" rel="noreferrer noopener">purchase of </a><a target="_blank" href="https://www.benzinga.com/general/biotech/23/12/36198526/pfizer-clears-required-regulatory-hurdles-to-complete-43b-seagen-acquisition" rel="noreferrer noopener">Seagen</a>.
The FT report highlights that Starboard <a target="_blank" href="https://www.ft.com/content/0f3e13bd-ba02-47a6-9261-1e49d19d6528" rel="noreferrer noopener">argues</a> that these moves, along with poor capital allocation, have contributed to Pfizer&#8217;s stock dropping over 50% from its pandemic peak. The activist investor will likely push for significant changes, possibly including a leadership overhaul or further divestitures.
With Pfizer&#8217;s stagnant revenue growth and limited options for quick fixes, Starboard&#8217;s path to reshaping the company remains uncertain.
Pfizer has already implemented cost-cutting measures and sold off divisions, leaving few levers for change.
Price Action: PFE stock is up 0.31% at $29.53 during the premarket session at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41310468/fda-approves-pfizers-second-hemophilia-drug-with-six-months" target="_blank" rel="noreferrer noopener">FDA Approves Pfizer&#8217;s Second Hemophilia Drug Within Six Months</a></li>
</ul>
Photo via Shutterstock

Biotech

Large Cap

Health Care

General

Guggenheim's Longstanding Pfizer Ties Tested Amid Starboard Battle

Roth MKM analyst Scott Stember reinstates O'Reilly Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>) with a Buy and announces $1337 price target.

ORLY

Roth MKM Reinstates Buy on O'Reilly Automotive, Announces $1337 Price Target

TD Cowen analyst Krish Sankar maintains Silvaco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVCO#NASDAQ">SVCO</a>) with a Buy and lowers the price target from $23 to $20.

SVCO

TD Cowen Maintains Buy on Silvaco Group, Lowers Price Target to $20

U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>) shares are<a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener"> trading higher on Wednesday.</a>
The company reported <a target="_blank" href="https://s203.q4cdn.com/711684571/files/doc_financials/2024/q3/Press-Release-3Q24.pdf" rel="noreferrer noopener">third-quarter</a> adjusted earnings per share of $1.03, beating the analyst <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41353142/u-s-bancorp-reports-third-quarter-2024-results" rel="noreferrer noopener">consensus estimate of 99 cents.</a>
Quarterly revenues of $6.864 billion missed the analyst consensus estimate of $6.895 billion.
The third quarter included $119 million of net losses on investment securities sales ($89 million net-of-tax), which was largely offset by lower income tax expenses, which reflected certain tax settlements.
&#8220;Our expense levels decreased year-over-year which supported modest positive operating leverage, excluding net securities losses and prior year notable items,&#8221; said Andy Cecere, Chairman and CEO, U.S. Bancorp.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41255250/banks-gear-up-for-earnings-season-15-top-stock-picks-including-citigroup-morgan-stanley-and-truist" rel="noreferrer noopener">Banks Gear Up For Earnings Season: 15 Top Stock Picks Including Citigroup, Morgan Stanley, And Truist</a>
Net interest income fell 2.4% to $4.135 billion in the quarter under review, due to the impact of higher interest rates on deposit mix and pricing. Third quarter noninterest income of $2.698 billion, down 2.4% year over year.
The provision for credit losses increased by $42 million (8.2%) compared with the third quarter of 2023, largely due to higher losses on credit card, commercial, and commercial real estate loans.
&#8220;Credit quality results were in line with expectations, and we continue to increase our capital position, ending the quarter with a CET1 capital ratio of 10.5%,&#8221; Cecere added. The CET1 capital ratio of 10.5% on September 30 was up from 10.3% on June 30.
The average total deposits for the third quarter were $3.5 billion, which was 0.7% lower year over year.
Price Action: USB shares are trading higher by 1.91% to $47.90 premarket at last check Wednesday.
Photo by JHVEPhoto via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41249837/s-p-500-earnings-season-kicks-off-why-analysts-call-this-quarter-a-stock-pickers-paradise" target="_blank" rel="noreferrer noopener">S&amp;P 500 Earnings Season Kicks Off: Why Analysts Call This Quarter ‘A Stock Picker's Paradise'</a></li>
</ul>

Earnings

Equities

Guidance

Markets

U.S. Bancorp Q3 Earnings: EPS Beat, Revenue Miss, Rising Credit Loss Provisions & More

<a href="https://www.bloomberg.com/news/articles/2024-10-16/blackrock-in-talks-with-ambani-for-india-private-credit-venture" title="https://www.bloomberg.com/news/articles/2024-10-16/blackrock-in-talks-with-ambani-for-india-private-credit-venture">https://www.bloomberg.com/news/articles/2024-10-16/blackrock-in-talks-with-ambani-for-india-private-credit-venture</a>

'BlackRock in Talks With Ambani for India Private Credit Venture' - Bloomberg

Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) and Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) are surging, with the former benefitting from social media chatter about Elon Musk <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41220500/elon-musk-says-potential-doge-department-under-a-trump-administration-will-be-a-garbage-co">heading a &#8220;D.O.G.E&#8221; department. </a>
What Happened: Dogecoin, Shiba Inu and Dogecoin-themed cryptocurrencies have performed exceptionally well over the past 24 hours:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price</td>
<td>Market cap</td>
<td>  24-hour trend</td>
<td>7-day trend</td>
</tr>
<tr>
<td>Dogecoin </td>
<td>$0.1256</td>
<td>$18.386B</td>
<td> +11.2%</td>
<td>+15.1%</td>
</tr>
<tr>
<td>Shiba Inu </td>
<td>$0.00001875</td>
<td>$11.04B</td>
<td> +5.2%</td>
<td>+7.2%</td>
</tr>
<tr>
<td>Department Of Government Efficiency (D.O.G.E)</td>
<td>$0.026</td>
<td>$25.68M</td>
<td>+122.4%</td>
<td>+152.4%</td>
</tr>
</tbody>
</table>
</figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41313977/dogecoins-on-chain-data-chart-patterns-flash-bullish-signals-this-top-analyst-thinks-its-a">Dogecoin&#8217;s On-Chain Data, Chart Patterns Flash Bullish Signals: This Top Analyst Thinks It&#8217;s A &#8216;Buy&#8217;</a>
Trader Notes: Crypto analysts are speculating on the potential impact of <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41313912/harris-or-trump-bitcoin-to-be-in-win-win-position-irrespective-of-who-wins-the-white-house">a Trump victory</a> in the upcoming U.S. presidential election on certain cryptocurrencies, particularly those associated with the &#8220;DOGE&#8221; narrative.
Andrew Kang <a href="https://x.com/Rewkang/status/1846231275847454786">suggests</a> that owning Dogecoin and other meme coins could be &#8220;one of the most interesting ways to express a &#8216;Trump Victory&#8217; trade.&#8221; He points to the increased likelihood of a <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39334602/arthur-hayes-raoul-pal-predict-dogecoin-etf-if-people-wait-in-line-for-luxury-brands-they-">Dogecoin ETF</a> and the potential creation of a<a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40780511/dogecoin-surges-8-as-elon-musk-jokes-doge-will-be-the-official-mascot-of-department-of-gov"> Department of Government Efficiency (DOGE)</a> under a Trump administration, which could keep the cryptocurrency in the headlines.
Supporting this view, analyst Unipcs <a href="https://x.com/theunipcs/status/1846474366684438605">highlights</a> the recent performance of DOGE-related assets, stating, &#8220;it&#8217;s hard not to be bullish on both doges if you really think Trump is going to win.&#8221; 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Statistics: IntoTheBlock data shows Dogecoin's large transaction volume increasing by 4.6% and daily active addresses falling by 1.5%. Transactions greater than $100,000 are up from&nbsp; 317 to 394 in a single day.
Shiba Inu's large transaction volume is down by 24.5% and daily active addresses are up by 17.2%. Shiba Inu has burned around 3 million SHIB coins from its ecosystem over the past 24 hours.
Community News: The official Dogecoin account picked up on a Shiba Inu-themed easter egg in Tesla&#8217;s Robotaxi presentation:
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Hey <a href="https://twitter.com/elonmusk?ref_src=twsrc%5Etfw">@elonmusk</a> is that a Shiba Inur taxi? <a href="https://t.co/ihfktgc4ds">pic.twitter.com/ihfktgc4ds</a>
&mdash; Dogecoin (@dogecoin) <a href="https://twitter.com/dogecoin/status/1844591727656448375?ref_src=twsrc%5Etfw">October 11, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Dogecoin-themed account Doge Designer <a href="https://x.com/cb_doge/status/1844595234316943841">noted</a> the same, wondering whether Musk would really allow purchases with Dogecoin in the future.
What&#8217;s Next: The influence of meme coins is expected to be thoroughly explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41312634/dogecoin-killer-shiba-inu-incinerates-277m-coins-in-1-transaction-watch-these-levels-for-a">&#8216;Dogecoin Killer&#8217; Shiba Inu Incinerates 277M Coins In 1 Transaction: Watch These Levels For A Bullish Rally</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$SHIB

Dogecoin Rockets Up 10%, Shiba Inu Spikes 5%: What Is Going On?

The soaring price of NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) stock over the last year has added to the wealth of CEO and co-founder Jensen Huang, making him one of th<a href="https://www.benzinga.com/news/management/24/10/41302431/elon-musk-to-end-year-as-richest-man-in-the-world-prediction-market-says-yes-higher-chance-than-l">e world's richest people.</a>
While Huang is humble about his growing wealth, here's a look at how close the Nvidia CEO is to cracking the top 10 list.
What Happened: In a recent interview, Huang said he <a href="https://www.benzinga.com/news/management/24/10/41294313/does-jensen-huang-check-nvidia-stock-price-daily">doesn't look at the daily price</a> of Nvidia stock and the price doesn't impact how good or bad he feels.
"Not every day, sometimes I'll look at the end of the day," Huang recently said.
Since he doesn't look at the stock price every day, Huang also probably doesn't keep an eye on the Bloomberg Billionaire's Index, which <a href="https://www.bloomberg.com/billionaires/?sref=TBDibEcD">ranks </a>the richest people in the world.
Huang has rapidly risen up the ranks, growing his wealth from $32 billion at the beginning of 2023 to $121 billion, now holding the 11th spot on the list.
While catching up to Elon Musk ($241 billion) might take years—or a significant decline in Tesla and SpaceX's value—Huang could break into the top 10 soon.
Huang trails Google co-founder Sergey Brin, who ranks 10th at $141 billion, by $20 billion.
Owning about 3.5% of Nvidia, which is his primary source of wealth, Huang would need Nvidia to gain $571.4 billion in market capitalization to surpass Brin.
Adding that much to the market capitalization would make Nvidia the most valuable company in the world once again with a value of $3.788 trillion, ranking ahead of Apple's $3.550 trillion.
This, of course, assumes Apple and Brin's wealth will stay the same in value.
Are you buying when the CEOs of the Magnificent 7 are selling?
<ul>
<li>Stay in the know with our Insider Trades page — <a href="https://www.benzinga.com/sec/insider-trades/">see when leaders like Mark Zuckerberg, Elon Musk, and Jensen Huang are offloading their own shares.</a></li>
</ul>
 Why It's Important: While adding $571 billion to a market capitalization would be no small feat, Nvidia has shown impressive valuation metrics in recent years.
Nvidia&nbsp;<a href="https://www.benzinga.com/news/23/05/32630114/nvidia-becomes-ninth-company-to-hit-1-trillion-market-cap-who-could-be-next-to-join-elusive-club" target="_blank" rel="noreferrer noopener">became a $1 trillion company</a>&nbsp;in May 2023 based on market capitalization, joining a limited number of public companies to hit the milestone.
It took the company less than nine months to reach a $2 trillion market capitalization after passing the $1 trillion milestone. Nvidia took even less time to go from $2 trillion to $3 trillion, hitting the milestone in 96 days and setting a new record for the short time between the two milestones.
Nvidia&nbsp;<a href="https://www.benzinga.com/news/24/06/39386946/microsoft-apple-step-aside-nvidia-is-now-the-most-valuable-public-company-in-the-world" target="_blank" rel="noreferrer noopener">briefly became the&nbsp;</a>world&#8217;s most valuable public company earlier this year, passing&nbsp;Apple&nbsp;and&nbsp;Microsoft. With a current market capitalization of $3.308 trillion, Nvidia narrowly trails first-place Apple ($3.466 trillion).
Huang has added $76.6 billion to his wealth in 2024 year-to-date, trailing only Meta Platforms CEO Mark Zuckerberg&#8216;s $80.8 billion gain, who ranks third on the list.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/education/24/10/41190198/if-you-invested-1-000-in-nvidia-stock-when-jensen-huang-got-company-logo-tattoo-heres-how-much-">If You Invested $1,000 In Nvidia Stock When Jensen Huang Got Company Logo Tattoo, Here&#8217;s How Much You&#8217;d Have Today</a></li>
</ul>
Photo: Shutterstock

Education

Management

NVDA

Jensen Huang Inches Closer To Top 10 Richest People In The World: Here's How Much More He Needs, How Much Nvidia Stock Must Rise

Keybanc analyst Matthew Gillmor maintains UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) with a Overweight and lowers the price target from $675 to $650.

Keybanc Maintains Overweight on UnitedHealth Group, Lowers Price Target to $650

TOVX

Theriva Biologics Granted Orphan Medicinal Product Designation By European Commission To VCN-01 For Treatment Of Retinoblastoma

ATXS

European Commission Grants Orphan Medicinal Product Designation To Astria Therapeutics' Navenibart For Treatment Of Hereditary Angioedema; Phase 1b/2 Trial Shows 90-96% Reduction In Monthly Attack Rates With Favorable Safety Profile

ALNY

Alnylam Submits Regulatory Application To European Medicines Agency For Vutrisiran To Treat ATTR Amyloidosis With Cardiomyopathy; Submission Based On HELIOS-B Phase 3 Results Showing Significant Reduction In Death And Cardiovascular Events

VP Jennifer Rebeles Contributes To Expert Panel Publishing Best Practices For Rare Sample Testing In Peer-Reviewed Journal

BIAF

bioAffinity's CyPath Lung Cancer Test Backed By New Flow Cytometry Guidelines

Novavax shares are trading lower after the FDA placed a clinical hold on the company's investigational new drug application for its COVID-19-influenza combination and standalone influenza vaccine candidates.

TNXP

Tonix Pharmaceuticals Submits NDA For TNX-102 SL To FDA For Fibromyalgia Treatment; Non-Opioid Analgesic Shows Significant Pain Reduction In Phase 3 Studies And Receives Fast Track Designation

<h3>Gainers</h3>
<ul>
<li>Container Store Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TCS#NYSE">TCS</a>) stock moved upwards by 41.5% to $15.14 during Wednesday's pre-market session. The market value of their outstanding shares is at $52.0 million. </li>
<li>Emerson Radio (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MSN#AMEX">MSN</a>) stock rose 10.09% to $0.55. The company's market cap stands at $11.6 million. </li>
<li>U Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCAR#NASDAQ">UCAR</a>) stock increased by 9.95% to $7.51. The market value of their outstanding shares is at $18.4 million. </li>
<li>Alta Global Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MMA#AMEX">MMA</a>) stock moved upwards by 9.89% to $1.57. The market value of their outstanding shares is at $16.4 million. </li>
<li>MEDIROM Healthcare Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRM#NASDAQ">MRM</a>) shares moved upwards by 7.5% to $3.86. The market value of their outstanding shares is at $19.0 million. </li>
<li>Cheetah Net Supply Chain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNT#NASDAQ">CTNT</a>) stock increased by 7.02% to $0.23. The company's market cap stands at $8.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Digital Brands Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) stock decreased by 21.0% to $0.18 during Wednesday's pre-market session. </li>
<li>Jiade (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JDZG#NASDAQ">JDZG</a>) shares fell 19.82% to $0.89. The market value of their outstanding shares is at $21.7 million. </li>
<li>TH International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THCH#NASDAQ">THCH</a>) shares declined by 12.37% to $0.61. The company's market cap stands at $96.9 million. </li>
<li>Ambow Education Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AMBO#AMEX">AMBO</a>) shares fell 9.55% to $1.8. The market value of their outstanding shares is at $5.1 million. </li>
<li>Connexa Sports Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YYAI#NASDAQ">YYAI</a>) shares fell 6.33% to $3.85. The market value of their outstanding shares is at $24.7 million. </li>
<li>Phoenix Motor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEV#NASDAQ">PEV</a>) shares declined by 6.25% to $0.72. The market value of their outstanding shares is at $26.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMBO

CTNT

DBGI

JDZG

THCH

UCAR

Connexa Sports Technologies Inc. - Common Stock

YYAI

12 Consumer Discretionary Stocks Moving In Wednesday's Pre-Market Session

ABVC Biopharma stock climbs on deal for its oncology/hematology products

ABVC BioPharma executes licensing agreement with OncoX

BACK, ZPTA and ABVC are among premarket gainers

PHG, IBRX and MESO are among premarket gainers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
ABVC BioPharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/abvc-stock-quote/">ABVC</a>) just reported results for the first quarter of 2024.<ul><li>ABVC BioPharma reported earnings per share of -40 cents.</li><li>The company reported revenue of $1,205.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/abvc-stock-earnings-abvc-biopharma-for-q1-of-2024/">ABVC Stock Earnings: ABVC BioPharma Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ABVC Stock Earnings: ABVC BioPharma Reported Results for Q1 2024

ABVC Biopharma files to sell 1M shares of common stock for holders

ABVC BioPharma, Inc. (ABVC) has issued an update. ABVC BioPharma has announced corrections to a previous press release concerning their licensing d...

ABVC BioPharma Corrects Licensing Deal Financials

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
ABVC BioPharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/abvc-stock-quote/">ABVC</a>) just reported results for the second quarter of 2024.<ul><li>ABVC BioPharma reported earnings per share of -9 cents.</li><li>The company reported revenue of $117,142.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/abvc-stock-earnings-abvc-biopharma-for-q2-of-2024/">ABVC Stock Earnings: ABVC BioPharma Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ABVC Stock Earnings: ABVC BioPharma Reported Results for Q2 2024

ABVC BioPharma GAAP EPS of -$0.09

An announcement from ABVC BioPharma, Inc. (ABVC) is now available. ABVC BioPharma, Inc. has recently updated its corporate presentation, details of...

ABVC BioPharma Releases Corporate Presentation Update

ABVC

AGBA

BACK

HOLO

HSAI

IBRX

ICLK

MESO

NIVF

SWIN

ZPTA

ZVSA

Press Releases

ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine

AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars

ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M

ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M

ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M

AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share

Small Cap

Opinion

Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection

ABVC BioPharma's CEO Discusses New Drug Development and AI Integration

ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements

Comments

ABVC BioPharma

Noticias

Últimas noticias sobre ABVC BioPharma (NASDAQ:ABVC) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL